Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

FDA-Approved MASH drug gets Real-World test in pakistan

NCT ID NCT07249788

Disease control Sponsor: Nabiqasim Industries (Pvt) Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests resmiterom, the first FDA-approved drug for MASH (a type of fatty liver disease), in 165 Pakistani patients. Researchers will check how safe it is and whether it improves liver health using non-invasive scans. The goal is to see if the drug works well in this specific population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Resmiterom (a drug for MASH, already FDA-approved)
What this could lead to
If successful, this could confirm resmiterom's safety and effectiveness for MASH in a broader population, supporting its use as a standard treatment.
What could go wrong
This is a Phase 4 study, so the drug is already approved, but it's open-label (no placebo) and limited to one country, which may affect how well results apply elsewhere. Side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension) * Clinical diagnosis of MASH using: * LSM ≥ 8.5kpa And/or * FAST score ≥0.67 And/or * FibroScan CAP ≥ 275 dB/m And/or * FIB-4 \> 1.3 Exclusion Criteria: * • History of drug addiction and alcoholism * Cirrhosis or decompensated liver disease * Chronic viral hepatitis HBV, HCV) * MACE including MI, Stroke, PE etc. * Pregnant/lactating women * Concurrent use of other investigational drugs * History of other liver diseases (viral, autoimmune, drug-induced, alcohol) * Previous use of resmetirom in last 6 months * Significant renal impairment (eGFR \<30)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mash - metabolic dysfunction-associated steatohepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mash - metabolic dysfunction-associated steatohepatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Liver transplant center, Holy family hospital

    RECRUITING

    Rawalpindi, Punjab Province, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.